{
    "clinical_study": {
        "@rank": "163266", 
        "acronym": "T1DMLIRA", 
        "arm_group": [
            {
                "arm_group_label": "Placebo + Insulin + Study 2", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Study 2: Cognitive performance test"
            }, 
            {
                "arm_group_label": "Liraglutide + Insulin + Study 2", 
                "arm_group_type": "Experimental", 
                "description": "Study 2: Cognitive performance test"
            }, 
            {
                "arm_group_label": "Liraglutide + Insulin + Study 1", 
                "arm_group_type": "Experimental", 
                "description": "Study 1: Gastric emptying test"
            }, 
            {
                "arm_group_label": "Placebo + Insulin + Study 1", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Study 1: Gastric emptying test"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to:\n\n      Part 1:\n\n      To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly\n      controlled patients and how the treatment affects gastric emptying rate during hypoglycemia.\n\n      Part 2:\n\n      To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects\n      counterregulatory hormones and cognitive performance during hypoglycemia."
        }, 
        "brief_title": "Liraglutide as add-on to Insulin in Type 1 Diabetes", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1", 
                "Hypoglycemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age: 18-70 years\n\n          -  BMI: 18-28\n\n          -  HbA1c \u2265 8 %\n\n          -  No residual \u03b2-cell function (glucagon test with c-peptide < 60 pM)\n\n          -  Caucasian\n\n          -  Diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive).\n\n          -  Remission phase must be completed\n\n          -  Female participants must use adequate contraception\n\n          -  Informed consent\n\n        Exclusion Criteria:\n\n          -  Overt diabetes complications; creatinin > 130 \u00b5M, proliferative retinopathy,\n             macroalbuminuria.\n\n          -  Autonomic neuropathy (RR-variation </=10 beats/min) and/or Orthostatic hypotension\n             (OH).\n\n          -  Anemia, Hb concentration; female <7.0 mmol/l, male<8.0 mmol/l\n\n          -  Pregnancy or lactation\n\n          -  Epilepsy\n\n          -  Use of antiepileptic medication\n\n          -  Use of beta blockers\n\n          -  Previously apoplexy cerebri.\n\n          -  Any use of benzodiazepine within the last month\n\n          -  Any use of neuroleptic drugs within the last six months\n\n          -  Self-perceived hearing loss\n\n          -  Alcohol or drug abuse\n\n          -  Allergy to the medication or placebo.\n\n          -  Treatment with any medication affecting glucose metabolism.\n\n          -  Any disorder which in the investigators opinion could interfere with the safety and\n             results of the trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02092896", 
            "org_study_id": "2012-002526-67", 
            "secondary_id": "2012-002526-67"
        }, 
        "intervention": [
            {
                "arm_group_label": "Liraglutide + Insulin + Study 1", 
                "description": "Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + Insulin + Study 1", 
                "description": "Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + Insulin + Study 2", 
                "description": "Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.", 
                "intervention_name": "Liraglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Liraglutide + Insulin + Study 2", 
                "description": "Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin", 
                "Hypoglycemic Agents", 
                "Glucagon-Like Peptide 1", 
                "Physiological Effects of Drugs"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diabetes Mellitus", 
            "Diabetes Mellitus, Type 1", 
            "Glucose Metabolism Disorders", 
            "Metabolic Diseases", 
            "Cognitive performance", 
            "Hypoglycemia", 
            "Insulin", 
            "Glucagon-Like Peptide 1", 
            "Hypoglycemic Agents", 
            "Physiological Effects of Drugs", 
            "Pharmacologic Actions", 
            "Incretins", 
            "Hormones"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "location": {
            "contact": {
                "email": "christian.seerup.frandsen@regionh.dk", 
                "last_name": "Christian SS Frandsen, MD", 
                "phone": "28136151"
            }, 
            "facility": {
                "address": {
                    "city": "Hvidovre", 
                    "country": "Denmark", 
                    "state": "Copenhagen", 
                    "zip": "2650"
                }, 
                "name": "Dept. of Endocrinology, Hvidovre University Hospital"
            }, 
            "investigator": {
                "last_name": "Christian SS Frandsen, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "4", 
        "official_title": "Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia", 
        "other_outcome": {
            "measure": "Frequency of Hypoglycemic episodes", 
            "safety_issue": "Yes", 
            "time_frame": "Week 0, week 12"
        }, 
        "overall_contact": {
            "email": "christian.seerup.frandsen@regionh.dk", 
            "last_name": "Christian SS Frandsen, MD", 
            "phone": "28136151"
        }, 
        "overall_official": {
            "affiliation": "Hvidovre University Hospital", 
            "last_name": "Christian SS Frandsen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Denmark: Danish Dataprotection Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in HbA1c (glycosylated haemoglobin)", 
                "safety_issue": "No", 
                "time_frame": "Week 0, week 12"
            }, 
            {
                "measure": "Changes from baseline in EEG and cognitive performances", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Change from baseline in gastric emptying rate", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02092896"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hvidovre University Hospital", 
            "investigator_full_name": "Christan SS Frandsen, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in glycemic control (CGM)", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Change from baseline in total daily insulin dose", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Changes from baseline in the counterregulatory hormone responses during hypoglycemia", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Change from baseline in body weight", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Change from baseline in auditory evoked potentials (AEP) during hypoglycemia", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Change from baseline in corrected QTc-interval (QTc) during hypoglycemia", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }, 
            {
                "measure": "Change from baseline in hypoglycemic symptom score", 
                "safety_issue": "No", 
                "time_frame": "week 0, week 12"
            }
        ], 
        "source": "Hvidovre University Hospital", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "NNF Center for Basal Metabolic Research, Denmark", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hillerod Hospital, Denmark", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Danish PhD School of Molecular Metabolism (Danish Diabetes Academy)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Novo Nordisk A/S", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hvidovre University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}